| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advancing the treatment of juvenile idiopathic arthritis
|
Murray, Grainne M
|
|
|
|
4 |
p. e294-e305
|
artikel
|
| 2 |
Alcohol and health: all, none, or somewhere in-between?
|
The Lancet Rheumatology,
|
|
|
|
4 |
p. e167
|
artikel
|
| 3 |
Analgesic effectiveness after total hip arthroplasty
|
Myles, Paul S
|
|
|
|
4 |
p. e190-e191
|
artikel
|
| 4 |
Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease
|
Frey, Sarah
|
|
|
|
4 |
p. e241-e243
|
artikel
|
| 5 |
A preoperative package of care for osteoarthritis, consisting of weight loss, orthotics, rehabilitation, and topical and oral analgesia (OPPORTUNITY): a two-centre, open-label, randomised controlled feasibility trial
|
Simpson, A Hamish R W
|
|
|
|
4 |
p. e237-e246
|
artikel
|
| 6 |
Assessment of treatment efficacy in polymyalgia rheumatica
|
Arends, Suzanne
|
|
|
|
4 |
p. e171-e173
|
artikel
|
| 7 |
Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study
|
Singla, Shikha
|
|
|
|
4 |
p. e200-e207
|
artikel
|
| 8 |
Cellular responses to SARS-CoV-2 vaccination after B-cell depletion: conflicting results from studies
|
Bhargava, Pavan
|
|
|
|
4 |
p. e247
|
artikel
|
| 9 |
Cellular responses to SARS-CoV-2 vaccination after B-cell depletion: conflicting results from studies – Authors' reply
|
Moor, Matthias B
|
|
|
|
4 |
p. e247-e248
|
artikel
|
| 10 |
ChatSLE: consulting ChatGPT-4 for 100 frequently asked lupus questions
|
Haase, Isabell
|
|
|
|
4 |
p. e196-e199
|
artikel
|
| 11 |
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials
|
Brun, Marthe Kirkesæther
|
|
|
|
4 |
p. e226-e236
|
artikel
|
| 12 |
Cognitive dysfunction in systemic lupus erythematosus: how do we advance our understanding?
|
Raghunath, Sudha
|
|
|
|
4 |
p. e293-e302
|
artikel
|
| 13 |
Communication combats hesitancy
|
The Lancet Rheumatology,
|
|
|
|
4 |
p. e235
|
artikel
|
| 14 |
Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials
|
Khouri, Charles
|
|
|
|
4 |
p. e237-e246
|
artikel
|
| 15 |
Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trial
|
Mulder, Michelle L M
|
|
|
|
4 |
p. e252-e261
|
artikel
|
| 16 |
Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study
|
Coates, Laura C
|
|
|
|
4 |
p. e262-e273
|
artikel
|
| 17 |
Complications and adverse events of unicompartmental versus total knee replacement
|
Sayers, Adrian
|
|
|
|
4 |
p. e199-e200
|
artikel
|
| 18 |
Correction to Lancet Rheumatol 2022; 4: e262–73
|
|
|
|
|
4 |
p. e249
|
artikel
|
| 19 |
Correction to Lancet Rheumatol 2019; 1: e229–36
|
|
|
|
|
4 |
p. e205
|
artikel
|
| 20 |
Correction to Lancet Rheumatol 2019; 1: e76–77
|
|
|
|
|
4 |
p. e205
|
artikel
|
| 21 |
Correction to Lancet Rheumatol 2019; 1: e23–34
|
|
|
|
|
4 |
p. e205
|
artikel
|
| 22 |
Correction to Lancet Rheumatol 2020; 2: e677–88
|
|
|
|
|
4 |
p. e250
|
artikel
|
| 23 |
Correction to Lancet Rheumatol 2020; 2: e666–76
|
|
|
|
|
4 |
p. e250
|
artikel
|
| 24 |
Correction to Lancet Rheumatol 2021; 3: e111–21
|
|
|
|
|
4 |
p. e250
|
artikel
|
| 25 |
COVID-19 cytokine storm: targeting the appropriate cytokine
|
Cron, Randy Q
|
|
|
|
4 |
p. e236-e237
|
artikel
|
| 26 |
COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
|
Putman, Michael
|
|
|
|
4 |
p. e237-e240
|
artikel
|
| 27 |
Disease heterogeneity in antineutrophil cytoplasmic antibody-associated vasculitis: implications for therapeutic approaches
|
Ford, Julia A
|
|
|
|
4 |
p. e247-e256
|
artikel
|
| 28 |
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials
|
Morand, Eric F
|
|
|
|
4 |
p. e282-e292
|
artikel
|
| 29 |
Evaluating the past might enlighten the future
|
van Suijlekom-Smit, Lisette WA
|
|
|
|
4 |
p. e197-e198
|
artikel
|
| 30 |
For lupus trials, the answer might depend on the question
|
Merrill, Joan T
|
|
|
|
4 |
p. e196-e197
|
artikel
|
| 31 |
Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study
|
Kearsley-Fleet, Lianne
|
|
|
|
4 |
p. e217-e226
|
artikel
|
| 32 |
Giant cell arteritis can occur in people of colour
|
Gill, Tiara
|
|
|
|
4 |
p. e175-e177
|
artikel
|
| 33 |
Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study
|
Topless, Ruth K
|
|
|
|
4 |
p. e274-e281
|
artikel
|
| 34 |
Hacking the inflammatory reflex
|
Tracey, Kevin J
|
|
|
|
4 |
p. e237-e239
|
artikel
|
| 35 |
Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts
|
Nguyen, Yann
|
|
|
|
4 |
p. e216-e225
|
artikel
|
| 36 |
IL-17 inhibition could fill treatment gap in psoriatic arthritis
|
Lubrano, Ennio
|
|
|
|
4 |
p. e199-e200
|
artikel
|
| 37 |
Immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children: a propensity-weighted cohort study
|
Channon-Wells, Samuel
|
|
|
|
4 |
p. e184-e199
|
artikel
|
| 38 |
Immunoglobulin, glucocorticoid, or combined therapy for multisystem inflammatory syndrome in children
|
Chew, Christine
|
|
|
|
4 |
p. e168-e169
|
artikel
|
| 39 |
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study
|
Cavalli, Giulio
|
|
|
|
4 |
p. e253-e261
|
artikel
|
| 40 |
Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation
|
Salvatierra, Juan
|
|
|
|
4 |
p. e248
|
artikel
|
| 41 |
Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply
|
Cavalli, Giulio
|
|
|
|
4 |
p. e248-e249
|
artikel
|
| 42 |
Is there a need for review-a-thons?
|
de Vries, Frank
|
|
|
|
4 |
p. e205
|
artikel
|
| 43 |
Is there a need for review-a-thons? – Authors' reply
|
Prieto-Alhambra, Daniel
|
|
|
|
4 |
p. e205-e207
|
artikel
|
| 44 |
Kimberly Templeton: creative change maker
|
Samarasekera, Udani
|
|
|
|
4 |
p. e183
|
artikel
|
| 45 |
Leflunomide in the treatment of psoriatic arthritis
|
López-Medina, Clementina
|
|
|
|
4 |
p. e230-e231
|
artikel
|
| 46 |
Long-awaited action on rare diseases
|
The Lancet Rheumatology,
|
|
|
|
4 |
p. e229
|
artikel
|
| 47 |
Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study
|
McInnes, Iain B
|
|
|
|
4 |
p. e227-e235
|
artikel
|
| 48 |
Long-term safety and efficacy of tofacitinib up to 48 months in psoriatic arthritis
|
Strand, Vibeke
|
|
|
|
4 |
p. e239-e240
|
artikel
|
| 49 |
Low-dose IL-2 for patients with systemic lupus erythematosus
|
He, Jing
|
|
|
|
4 |
p. e203
|
artikel
|
| 50 |
Low-dose IL-2 for patients with systemic lupus erythematosus – Authors' reply
|
Humrich, Jens Y
|
|
|
|
4 |
p. e203-e204
|
artikel
|
| 51 |
Medical cannabis: bridging the evidence gap
|
The Lancet Rheumatology,
|
|
|
|
4 |
p. e195
|
artikel
|
| 52 |
Metformin in SLE: metabolism as a therapeutic target in autoimmune disease
|
Nikpour, Mandana
|
|
|
|
4 |
p. e196-e197
|
artikel
|
| 53 |
Methotrexate in rheumatoid arthritis—another brick in the wall
|
Rubbert-Roth, Andrea
|
|
|
|
4 |
p. e173-e175
|
artikel
|
| 54 |
Misconceptions of arthritis and age: shake me, I rattle
|
Harding, Emilia
|
|
|
|
4 |
p. e207
|
artikel
|
| 55 |
Non-invasive vagus nerve stimulation for rheumatoid arthritis: a proof-of-concept study
|
Marsal, Sara
|
|
|
|
4 |
p. e262-e269
|
artikel
|
| 56 |
Non-opioid analgesic combinations following total hip arthroplasty (RECIPE): a randomised, placebo-controlled, blinded, multicentre trial
|
Steiness, Joakim
|
|
|
|
4 |
p. e205-e215
|
artikel
|
| 57 |
Not growing out of it
|
Fletcher-Lloyd, Nan
|
|
|
|
4 |
p. e203-e204
|
artikel
|
| 58 |
Opioid use, postoperative complications, and implant survival after unicompartmental versus total knee replacement: a population-based network study
|
Burn, Edward
|
|
|
|
4 |
p. e229-e236
|
artikel
|
| 59 |
Patient-led research in rheumatology: the way forward?
|
Berkovic, Danielle
|
|
|
|
4 |
p. e180
|
artikel
|
| 60 |
Patient–researcher co-presentation of research results to people living with systemic sclerosis
|
Cook, Vanessa
|
|
|
|
4 |
p. e180-e181
|
artikel
|
| 61 |
Perspective of patients with autoimmune diseases on COVID-19 vaccination
|
Boekel, Laura
|
|
|
|
4 |
p. e241-e243
|
artikel
|
| 62 |
Poor phase 4 safety results for tofacitinib raise questions about JAK inhibitors
|
Owens, Brian
|
|
|
|
4 |
p. e252
|
artikel
|
| 63 |
Pre-scleroderma and new opportunities for preventive medicine
|
Benfaremo, Devis
|
|
|
|
4 |
p. e200
|
artikel
|
| 64 |
Pre-scleroderma and new opportunities for preventive medicine – Authors’ reply
|
Lescoat, Alain
|
|
|
|
4 |
p. e201
|
artikel
|
| 65 |
Prevention of psoriatic arthritis: the next frontier
|
Ogdie, Alexis
|
|
|
|
4 |
p. e170-e171
|
artikel
|
| 66 |
Psoriatic arthritis in developing and resource-poor countries
|
Maharaj, Ajesh B
|
|
|
|
4 |
p. e200-e202
|
artikel
|
| 67 |
Raynaud's phenomenon: no net effects of vasodilators in a network analysis
|
Jaeger, Veronika K
|
|
|
|
4 |
p. e200-e202
|
artikel
|
| 68 |
Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial
|
Tamai, Hiroya
|
|
|
|
4 |
p. e215-e224
|
artikel
|
| 69 |
Reproductive health in rheumatic disease: knowledge is power
|
The Lancet Rheumatology,
|
|
|
|
4 |
p. e195
|
artikel
|
| 70 |
Repurposing antidiabetic medications for gout: the potential of sodium glucose co-transporter 2 inhibitors
|
Neogi, Tuhina
|
|
|
|
4 |
p. e197-e199
|
artikel
|
| 71 |
Research in Brief
|
Thorley, Jennifer
|
|
|
|
4 |
p. e250
|
artikel
|
| 72 |
Research in Brief
|
Thorley, Jennifer
|
|
|
|
4 |
p. e206
|
artikel
|
| 73 |
Research in Brief
|
Thorley, Jennifer
|
|
|
|
4 |
p. e251
|
artikel
|
| 74 |
Research in Brief
|
Thorley, Jennifer
|
|
|
|
4 |
p. e208
|
artikel
|
| 75 |
Research in Brief
|
Thorley, Jennifer
|
|
|
|
4 |
p. e182
|
artikel
|
| 76 |
Research in Brief
|
Thorley, Jennifer
|
|
|
|
4 |
p. e202
|
artikel
|
| 77 |
Safety and efficacy of metformin in systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial
|
Sun, Fangfang
|
|
|
|
4 |
p. e210-e216
|
artikel
|
| 78 |
Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
|
Nash, Peter
|
|
|
|
4 |
p. e270-e283
|
artikel
|
| 79 |
Shifting the mindset—adolescent and young adult rheumatology in transition
|
Willis, Emily
|
|
|
|
4 |
p. e236-e244
|
artikel
|
| 80 |
Strategy lessons from a new clinical trial in psoriatic arthritis
|
Kuchinad, Kamini
|
|
|
|
4 |
p. e231-e232
|
artikel
|
| 81 |
Subgroups of Sjögren's disease: are they of any help?
|
Arends, Suzanne
|
|
|
|
4 |
p. e191-e193
|
artikel
|
| 82 |
Surveillance of congenital heart block in highly specialised care
|
Sonesson, Sven-Erik
|
|
|
|
4 |
p. e203-e204
|
artikel
|
| 83 |
Surveillance of congenital heart block in highly specialised care – Authors' reply
|
Costedoat-Chalumeau, Nathalie
|
|
|
|
4 |
p. e204-e205
|
artikel
|
| 84 |
Systemic sclerosis and COVID-19 vaccines: a SPIN Cohort study
|
Gordon, Jessica K
|
|
|
|
4 |
p. e243-e246
|
artikel
|
| 85 |
Tackling heterogeneity in Sjögren's disease
|
The Lancet Rheumatology,
|
|
|
|
4 |
p. e189
|
artikel
|
| 86 |
Thank you to our contributors and peer reviewers in 2022
|
The Lancet Rheumatology Editors,
|
|
|
|
4 |
p. e177
|
artikel
|
| 87 |
Thank you to The Lancet Rheumatology's peer reviewers in 2022
|
The Lancet Rheumatology Editors,
|
|
|
|
4 |
p. e177-e179
|
artikel
|
| 88 |
The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program
|
Li, JingWei
|
|
|
|
4 |
p. e220-e228
|
artikel
|
| 89 |
The impact of autoantibodies against citrullinated, carbamylated, and acetylated peptides on radiographic progression in patients with new-onset rheumatoid arthritis: an observational cohort study
|
Nijjar, Jagtar S
|
|
|
|
4 |
p. e284-e293
|
artikel
|
| 90 |
The influence of sex hormones on musculoskeletal pain and osteoarthritis
|
Gulati, Malvika
|
|
|
|
4 |
p. e225-e238
|
artikel
|
| 91 |
The nosology of systemic sclerosis: how lessons from the past offer new challenges in reframing an idiopathic rheumatological disorder
|
Lescoat, Alain
|
|
|
|
4 |
p. e257-e264
|
artikel
|
| 92 |
Therapeutic drug monitoring countering the effect of anti-infliximab antibodies
|
Hooijberg, Femke
|
|
|
|
4 |
p. e193-e194
|
artikel
|
| 93 |
The unsustainable bubble of disease-modifying antirheumatic drugs in rheumatology
|
Landewé, Robert B M
|
|
|
|
4 |
p. e306-e312
|
artikel
|
| 94 |
Time to talk to adults with rheumatic diseases about herpes zoster vaccination
|
Pier, Mischa
|
|
|
|
4 |
p. e247-e251
|
artikel
|
| 95 |
Titilola (Lola) Falasinnu: looking out for the overlooked
|
Morgan, Jules
|
|
|
|
4 |
p. e251
|
artikel
|
| 96 |
Toxic epidermal necrosis-like acute cutaneous lupus erythematosus
|
Suzuki, Koji
|
|
|
|
4 |
p. e252
|
artikel
|
| 97 |
Type I interferon, anti-interferon antibodies, and COVID-19
|
Calabrese, Leonard H
|
|
|
|
4 |
p. e246-e247
|
artikel
|
| 98 |
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
|
Furie, Richard A
|
|
|
|
4 |
p. e208-e219
|
artikel
|
| 99 |
Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases
|
Felten, Renaud
|
|
|
|
4 |
p. e243-e245
|
artikel
|
| 100 |
When should we treat knee osteoarthritis and with which treatments?
|
Haber, Travis
|
|
|
|
4 |
p. e195-e196
|
artikel
|
| 101 |
Who will respond to type I interferon receptor blockade in SLE?
|
Aringer, Martin
|
|
|
|
4 |
p. e234-e236
|
artikel
|
| 102 |
William Heberden
|
Burki, Talha Khan
|
|
|
|
4 |
p. e209
|
artikel
|
| 103 |
Women with gout and COVID-19—an unfortunate combination?
|
Nissen, Christoffer B
|
|
|
|
4 |
p. e233-e234
|
artikel
|
| 104 |
1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial
|
Bolhuis, Thomas E
|
|
|
|
4 |
p. e208-e214
|
artikel
|
Tijdschrift beschrijving